HK1166130A1 - Use of s-erbb-3 as a marker for cancer s-erbb-3 - Google Patents

Use of s-erbb-3 as a marker for cancer s-erbb-3

Info

Publication number
HK1166130A1
HK1166130A1 HK12106824.5A HK12106824A HK1166130A1 HK 1166130 A1 HK1166130 A1 HK 1166130A1 HK 12106824 A HK12106824 A HK 12106824A HK 1166130 A1 HK1166130 A1 HK 1166130A1
Authority
HK
Hong Kong
Prior art keywords
erbb
marker
cancer
Prior art date
Application number
HK12106824.5A
Other languages
English (en)
Chinese (zh)
Inventor
Sandra Rutz
Bernhard Eckert
Peter Heiss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1166130A1 publication Critical patent/HK1166130A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
HK12106824.5A 2009-02-24 2012-07-11 Use of s-erbb-3 as a marker for cancer s-erbb-3 HK1166130A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09002586 2009-02-24
PCT/EP2010/001087 WO2010097186A1 (fr) 2009-02-24 2010-02-22 Utilisation de s-erbb-3 comme marqueur des cancers

Publications (1)

Publication Number Publication Date
HK1166130A1 true HK1166130A1 (en) 2012-10-19

Family

ID=40456830

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106824.5A HK1166130A1 (en) 2009-02-24 2012-07-11 Use of s-erbb-3 as a marker for cancer s-erbb-3

Country Status (8)

Country Link
US (1) US20110269158A1 (fr)
EP (1) EP2401621B1 (fr)
JP (1) JP5384672B2 (fr)
CN (1) CN102326081B (fr)
CA (1) CA2753119A1 (fr)
ES (1) ES2434017T3 (fr)
HK (1) HK1166130A1 (fr)
WO (1) WO2010097186A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2856205A1 (fr) * 2011-11-15 2013-05-23 Oncocyte Corporation Procedes et compositions pour le traitement et le diagnostic du cancer de la vessie
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
WO2015048008A2 (fr) 2013-09-24 2015-04-02 Medimmune, Llc Molécules de liaison spécifiques de her3 et utilisation desdites molécules
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
WO2016011432A2 (fr) 2014-07-17 2016-01-21 Czerniecki Brian J Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
KR102328327B1 (ko) * 2014-09-26 2021-11-22 소마로직, 인크. 심혈관 위험 사건 예측 및 이의 용도
CN104449482A (zh) * 2014-11-05 2015-03-25 苏州培华电子材料有限公司 一种亚克力胶配方及其制备方法
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
EP3325005A4 (fr) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
CN113683698B (zh) * 2017-06-22 2023-03-31 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
CN111289748A (zh) * 2018-12-08 2020-06-16 惠州市中大惠亚医院 ErbB3蛋白在制备膀胱癌无创诊断产品中的应用
WO2020124065A1 (fr) * 2018-12-14 2020-06-18 The Regents Of The University Of California Détection simultanée d'isoformes protéiques et d'acides nucléiques à partir de nombres de cellules de départ faibles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2002023200A2 (fr) 2000-09-11 2002-03-21 Ciphergen Biosystems, Inc. Biomarqueurs humains du cancer du sein
US7612042B2 (en) * 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
US7744882B2 (en) * 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos

Also Published As

Publication number Publication date
CN102326081B (zh) 2014-11-19
ES2434017T3 (es) 2013-12-13
JP2012518779A (ja) 2012-08-16
EP2401621B1 (fr) 2013-08-14
US20110269158A1 (en) 2011-11-03
CN102326081A (zh) 2012-01-18
WO2010097186A1 (fr) 2010-09-02
CA2753119A1 (fr) 2010-09-02
EP2401621A1 (fr) 2012-01-04
WO2010097186A8 (fr) 2011-08-11
JP5384672B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
HK1166130A1 (en) Use of s-erbb-3 as a marker for cancer s-erbb-3
HK1222207A1 (zh) 通過甲基化標記物來診斷癌症
PT2456889E (pt) Marcadores para o cancro do endométrio
GB0907874D0 (en) Skin marker
HK1169168A1 (en) Use of dppiv/seprase as a marker for cancer dppiv/seprase
ZA201108131B (en) Dihydroorotate- dehydrogenasee inhibitors as virostatic compounds
GB0922437D0 (en) Hypoxia tumour markers
PL3438651T3 (pl) Zastosowania substancji markerów
HK1170566A1 (en) Secernin-1 as a marker for cancer -1
EP2495561A4 (fr) Marqueur permettant de déterminer la sensibilité à un agent anticancéreux
ZA201200888B (en) New tumor marker
EP2427183A4 (fr) Composés thérapeutiques
GB0908071D0 (en) Marker
HK1165204A1 (en) Cybp as a marker of lung cancer cybp
EP2467140A4 (fr) Procédé de traitement du cancer
HK1184221A1 (zh) 作為厄洛替尼治療的標誌物的 複合物
GB0905964D0 (en) Marker
EP2496704A4 (fr) Composés thérapeutiques
IL220316A (en) Mitf as a marker of cancer tendency
GB2494830B (en) Underwater marker
GB201014687D0 (en) Tile marker
EP2456309A4 (fr) Composés thérapeutiques
GB0906026D0 (en) Therapeutic compounds
GB201005705D0 (en) Cancer markers
GB201015913D0 (en) Marker

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190217